COMP <GO>
KYNB vs PBM // EV/EBITDA & P/E VALUATION
Kyntra Bio Inc. (NASDAQ) VS. Psyence Biomedical Ltd. (NASDAQ) • 15-METRIC TALLY: KYNB 0
— PBM 2
■ METRIC PARITY
LAST: $4.65 (-1.48%) • MKT CAP: $18.8M
valuation
—
LAST: $3.61 (+6.18%) • MKT CAP: $19.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYNB VS. PBM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KYNB | PBM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 91.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | 68.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -65.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 26.9 | 35.1 | -8.18 | PBM | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.8M | $19.2M | -$361.0K | PBM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KYNB REV | PBM REV | KYNB GROSS % | PBM GROSS % | KYNB FCF | PBM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $6.4M | — | 91.4% | — | -$4.8M | — |
| FY 2024 | $29.6M | — | 47.5% | — | -$138.3M | — |
| FY 2023 | $46.8M | — | — | — | -$315.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYNB // BETA —
PBM // BETA —